The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden

Clinical Therapeutics

Volumn 27, Issue 1, 2005, Pages 100-110

  Lindgren, Peter ^a,b   Stenestrand, Ulf ^c   Malmberg, Klas ^d   Jönsson, Bengt ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Clopidogrel; Decision analysis; Economic evaluation; Sweden

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTICLE; COMPUTER MODEL; CORONARY CARE UNIT; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; PERCUTANEOUS CORONARY INTERVENTION;

EID: 14844290286     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.01.008     Document Type: Article

References (24)

1. [published corrections appear in N Engl J Med. 2001;345:1716 and N Engl J Med. 2001;345:1506] Yusuf S., Zhao F., and Mehta S.R. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation N Engl J Med 345 2001 494 502
2. Lindgren P., Jönsson B., and Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: A longterm model based on the CURE trial J Intern Med 255 2004 562 570
3. Lamy A., Jönsson B., and Weintraub W.S. The costeffectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study Eur J Cardiovasc Prev Rehabil 11 2004 460 465
4. Mehta S.R., Yusuf S., and Peters R.J. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: ThePCI-CURE study Lancet 358 2001 527 533
5. Chicago, Ill. Mehta S.R., Weintraub W.S., and Jonsson B. Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial: The PCI-CURE economic analysis Poster presented at: 52nd Scientific Session of the American College of Cardiology March 30-April 4, 2003
6. Naimark D., Krahn M.D., and Naglie G. Primer on medical decision analysis: Part 5-Working with Markov processes Med Decis Making 17 1997 152 159
7. Markov modeling, analysis and microstimulation with the health care module TreeAge Pro Health Care Users Manual 2004 TreeAge Software, Inc Williamstown, Mass 59 128
8. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: A practical guide Med Decis Making 13 1993 322 338
9. Halpern E.F., Weinstein M.C., Hunink M.G., and Gazelle G.S. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients Med Decis Making 20 2000 314 322
10. Lothgren M., and Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves Health Econ 9 2000 623 630
11. hia.se Swedish Register of Information and Knowledge aboutSwedish Heart Intensive care Admissions Web site.
12. Zethraeus N., Molin T., Henriksson P., and Jonsson B. Costs of coronary heart disease and stroke: The case of Sweden J Intern Med 246 1999 151 159
13. Johannesson M. At what coronary risk level is it costeffective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 22 2001 919 925
14. Jonsson B. Economics of drug treatment: For which patients is it cost-effective to lower cholesterol? Lancet 358 2001 1251 1256
15. Meltzer D. Accounting for future costs in medical costeffectiveness analysis J Health Econ 16 1997 33 64
16. Ekman M. Two Essays in Health Economics: Consumption and Production by Age, with Emphasis on Health Care Expenditures and Economic Evaluation ofBeta-Blocker Therapy in Heart Failure 2001 Stockholm School of Economics Stockholm, Sweden
17. Statistics Sweden Web site.
18. Available at: The Bank of Sweden Interest and exchange rates Accessed September 24, 2003
19. General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board 2003 Pharmaceutical Benefits Board Stockholm, Sweden
20. Fenwick E., O'Brien B.J., and Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions Health Econ 13 2004 405 415
21. Murray C.J., Lauer J.A., and Hutubessy R.C. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on re duction of cardiovascular disease risk Lancet 361 2003 717 725
22. Mark D.B., Harrington R.A., and Lincoff A.M. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes Circulation 101 2000 366 371
23. Johannesson M., Jönsson B., Kjekshus J. Scandinavian Simvastatin Survival Study Group Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease N Engl J Med 336 1997 332 336
24. Abstract 1137-77 Weintraub W.S., Mahoney E.M., and Mehta S. Long-term costeffectiveness of clopidogrel in pa tients having percutaneous coronary intervention early after acute coronary syndrome: Results fromPCI-CURE J Am Coll Cardiol 43 Suppl 2 2004 A296